Drug name confusion, particularly because of look-alike, sound-alike (LASA) name attributes can be a contributing factor to medication related adverse events. TALLman lettering is one of many risk mitigation strategies to minimize errors involving LASA drug names.
ISMP Canada invites healthcare professionals to participate in a one hour complimentary webinar that will provide an opportunity for participants to learn more about the development of a list of "TALLman Lettering for Look-alike/Sound-Alike Drug Names in Canada".Learning Objectives:
At the end of the webinar, participants will:
- Understand the methodology used to apply TALLman lettering to selected LASA drug name pairs of concern in Canada.
- Learn about the principles for applying TALLman lettering in Canada.
- Consider alternative and complementary strategies that can be used to reduce the risk of errors associated with look-alike, sound-alike (LASA) drug names.
Healthcare professionals involved in procurement, prescribing, dispensing, transcribing and administering look-alike, sound alike drugs; pharmacy managers who oversee patient safety activities, clinical informatics personnel involved in the development or implementation of IT medication management systems; administrators; quality and risk management personnel and those interested in patient safety in general.